|
|
 |
|
Viewing report
|
|
|
|
Netherlands Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to
Global Markets Direct, Nov 2008, Pages: 81
1 2
1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 10
2.1 What Is This Report About? 10
3 Definitions of the Markets Covered in the Report 11
3.1 Diabetes Care Devices 11
3.2 Glucose Monitoring 11
3.2.1 Blood Glucose Meter 11
3.2.2 Blood Glucose Strips 11
3.3 Insulin Delivery 11
3.3.1 Insulin Pen 11
3.3.2 Insulin Pump 11
3.3.3 Insulin Syringes 12
4 Healthcare Sector Review 13
4.1 Healthcare Expenditure 13
4.2 Healthcare Infrastructure 16
4.3 Healthcare Policy 18
4.3.1 Health Insurance Act 19
4.3.2 Healthcare Allowance Act 19
4.3.3 The Exceptional Medical Expenses Act 19
5 Regulation System 20
5.1 Medical Equipment Approval Process 20
5.1.1 Classification of Medical Devices 21
5.1.2 Conformity Assessment Process 30
5.1.2.1 Class I devices 30
5.1.2.2 Class IIa devices 31
5.1.2.3 Class IIb devices 32
5.1.2.4 Class III devices 33
5.2 Post Market Surveillance (PMS) 33
6 Pricing and Reimbursement 34
6.1 Pricing and Reimbursement in Netherlands 34
7 Distribution Structure 35
7.1 Distribution Structure in Netherlands 35
8 Diabetes Care Devices In Netherlands 36
8.1 Diabetes Care Devices Cross Country Comparison (2000-2012) 36
8.2 Diabetes Care Devices, Netherlands, Overall Revenues ($ mn), 2000-2012 37
8.3 Diabetes Care Devices, Netherlands, Category Volume (Units), 2000-2012 41
8.4 Diabetes Care Devices, Netherlands Company share (2006-2007) 44
9 Glucose Monitoring In Netherlands 45
9.1 Glucose Monitoring Overall Revenue (2000-2012) 45
9.2 Glucose Monitoring Overall Volume (2000-2012) 47
9.3 Glucose Monitoring Average Price (2000-2012) 49
9.4 Glucose Monitoring Distribution Share (2006-2007) 49
9.5 Glucose Monitoring, Netherlands, Company Share (2006-2007) 50
10 Insulin Delivery In Netherlands 51
10.1 Insulin Delivery Overall Revenue (2000-2012) 51
10.2 Insulin Delivery Overall Volume (2000-2012) 53
10.3 Insulin Delivery Average Price (2000-2012) 54
10.4 Insulin Delivery Distribution Share (2006-2007) 54
10.5 Insulin Delivery, Netherlands, Company Share (2006-2007) 55
11 F. Hoffmann-La Roche Ltd. Company Profile 56
11.1 Company Overview 56
11.2 Value Chain Analysis 56
11.2.1 Manufacturing 57
11.2.1.1 In House Manufacturing 57
11.2.1.2 Outsourcing 57
11.2.2 Product Development 57
11.2.2.1 Regulatory Approvals 57
11.2.2.2 Clinical Trials 57
11.2.2.3 Research and Development 57
11.2.3 Sales and Marketing 58
11.2.3.1 Partnerships and Alliances 58
11.2.3.2 Licensing Agreements 58
12 LifeScan, Inc. Company Profile 59
12.1 Company Overview 59
12.1.1 LifeScan, Inc. Pipeline Products by Equipment Type 59
12.1.2 LifeScan, Inc. Pipeline Products by Development Stage 59
12.1.3 LifeScan, Inc. Pipeline Products By Therapy Area 59
12.1.4 LifeScan, Inc. Pipeline Products By Clinical Trials 60
12.1.5 LifeScan, Inc. Pipeline Products By News Summary 60
13 Bayer HealthCare AG Company Profile 61
13.1 Company Overview 61
13.2 Value Chain Analysis 61
13.2.1 Manufacturing 62
13.2.1.1 In House Manufacturing 62
13.2.1.2 Outsourcing 62
13.2.2 Product Development 62
13.2.2.1 Regulatory Approvals 62
13.2.2.2 Clinical Trials 62
13.2.2.3 Research and Development 62
13.2.3 Sales and Marketing 63
13.2.3.1 Partnerships and Alliances 63
13.2.3.2 Licensing Agreements 63
13.3 Bayer HealthCare AG Pipeline Products 63
13.3.1 Bayer HealthCare AG Pipeline Products by Equipment Type 63
13.3.2 Bayer HealthCare AG Pipeline Products by Development Stage 63
13.3.3 Bayer HealthCare AG Pipeline Products by Therapy Area 64
13.3.4 Bayer HealthCare AG Pipeline Products by News Summary 64
14 Novo Nordisk A/S Company Profile 65
14.1 Company Overview 65
14.1.1 Novo Nordisk A/S Pipeline Products By Equipment Type 65
14.1.2 Novo Nordisk A/S Pipeline Products By Development Stage 65
14.1.3 Novo Nordisk A/S Pipeline Products by Therapy Area 66
14.1.4 Novo Nordisk A/S Pipeline Products by Clinical Trials 66
15 Abbott Laboratories Company Profile 67
15.1 Company Overview 67
15.2 Value Chain Analysis 67
15.2.1 Manufacturing 68
15.2.1.1 In House Manufacturing 68
15.2.2 Product Development 68
15.2.2.1 Regulatory Approvals 68
15.2.2.2 Research and Development 68
15.2.2.3 Clinical Trials 68
15.2.3 Sales and Marketing 69
15.2.3.1 Partnerships and Alliances 69
15.2.4 Abbott Laboratories Pipeline Products By Equipment Type 69
15.2.5 Abbott Laboratories Pipeline Products By Development Stage 69
15.2.6 Abbott Laboratories Pipeline Products by Therapy Area 70
15.2.7 Abbott Laboratories Pipeline Products by Clinical Trials 70
15.2.8 Abbott Laboratories Pipeline Products by News Summary 70
16 Eli Lilly and Company Company Profile 71
16.1 Company Overview 71
16.2 Value Chain Analysis 71
16.2.1 Manufacturing 72
16.2.1.1 In House Manufacturing 72
16.2.1.2 Outsourcing 72
16.2.2 Product Development 72
16.2.2.1 Regulatory Approvals 72
16.2.2.2 Clinical Trials 72
16.2.2.3 Research and Development 72
16.2.3 Sales and Marketing 73
16.2.3.1 Partnerships and Alliances 73
16.2.3.2 Licensing Agreements 73
16.2.3.3 E-distribution 73
16.2.4 Eli Lilly and Company Pipeline Products By Equipment Type. 74
16.2.5 Eli Lilly and Company Pipeline Products by Development Stage 74
16.2.6 Eli Lilly and Company Pipeline Products By Therapy Area 74
17 Diabetes Management International BV Company Profile 75
17.1 Company Overview 75
18 Appendix 76
18.1 Global Markets Direct Research Methodology 76
18.2 Coverage 77
18.3 Secondary Research 77
18.4 Primary Research 78
18.5 Models 78
18.6 Forecasts 79
18.7 Expert Panels 79
18.8 Currency Conversion 80
18.9 Contact Us 81
18.10 Disclaimer 81
Executive Summary
1.2 List of Figures
Figure 1: Total Healthcare Expenditure in Netherlands, 2000 - 2006 14
Figure 2: Healthcare Financing Framework in Netherlands, 2005 15
Figure 3: Flowchart for Classification of Non-invasive Devices in Netherlands, 2007 22
Figure 4: Flowchart for Classification of Invasive Devices in Netherlands, 2007 23
Figure 5: Flowchart for Classification of Invasive Devices in Netherlands, 2007 24
Figure 6: Flowchart for Classification of Invasive Devices in Netherlands, 2007 25
Figure 7: Flowchart for Classification of Invasive Devices in Netherlands, 2007 26
Figure 8: Flowchart for Classification of Active Devices in Netherlands, 2007 27
Figure 9: Flowchart for Classification of Active Devices in Netherlands, 2007 28
Figure 10: Flowchart for Classification of Devices except Non-invasive, Invasive and Active Devices in Netherlands, 2007 29
Figure 11: Conformity Assessment of Class-I Medical Devices in Netherlands, 2007 30
Figure 12: Conformity Assessment of Class-IIa Medical Devices in Netherlands, 2007 31
Figure 13: Conformity Assessment of Class-IIb Medical Devices in Netherlands, 2007 32
Figure 14: Conformity Assessment of Class-III Medical Devices in Netherlands, 2007 33
Figure 15: Diabetes Care Devices Cross Country Comparison (2000-2012) 36
Figure 16: Diabetes Care Devices, Netherlands, Overall Revenues ($ mn), 2000-2012 37
Figure 17: Diabetes Care Devices, Egypt, Portfolio Analysis, 2000-2012 38
Figure 18: Diabetes Care Devices, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007 39
Figure 19: Diabetes Care Devices, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012 40
Figure 20: Diabetes Care Devices, Netherlands, Category Volume (Units), 2000-2012 41
Figure 21: Diabetes Care Devices, Netherlands, Category Volume (Units), Historic, 2000-2007 42
Figure 22: Diabetes Care Devices, Netherlands, Category Volume (Units), Forecast, 2007-2012 43
Figure 23: Diabetes Care Devices, Netherlands Company share (%), 2007 44
Figure 24: Glucose Monitoring, Netherlands, Revenue ($ mn) by Segment , Historic, 2000-2007 45
Figure 25: Glucose Monitoring, Netherlands, Revenue ($ mn) by Segment , Forecast, 2007-2012 46
Figure 26: Glucose Monitoring, Netherlands, Overall Volume (Units), Historic, 2000-2007 47
Figure 27: Glucose Monitoring, Netherlands, Overall Volume (Units), Forecast, 2007-2012 48
Figure 28: Glucose Monitoring, Netherlands, Company Share (%), 2007 50
Figure 29: Insulin Delivery, Netherlands, Revenue ($ mn) by Segment , Historic, 2000-2007 51
Figure 30: Insulin Delivery, Netherlands, Revenue ($ mn) by Segment , Forecast, 2007-2012 52
Figure 31: Insulin Delivery, Netherlands, Company Share (%), 2007 55
Figure 32: F. Hoffmann-La Roche Ltd Value Chain Analysis 56
Figure 33: Bayer HealthCare AG Value Chain Analysis 61
Figure 34: Abbott Laboratories Value Chain Analysis 67
Figure 35: Eli Lilly and Company Value Chain Analysis 71
Figure 36: Global Markets Direct Methodology 76
Customers who bought this item also bought
Netherlands Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2015
Global Diabetes Care Devices Market Analysis and Forecasts to 2015
Canada Diabetes Care Devices Market Analysis and Forecasts to 2015
France Diabetes Care Devices Market Analysis and Forecasts to 2015
Italy Diabetes Care Devices Market Analysis and Forecasts to 2015
Spain Diabetes Care Devices Market Analysis and Forecasts to 2015
Australia Diabetes Care Devices Market Analysis and Forecasts to 2015
Brazil Diabetes Care Devices Market Analysis and Forecasts to 2015
UK Diabetes Care Devices Market Analysis and Forecasts to 2015
The Future of the Diabetes Care Devices Market to 2015
Belgium Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2012
Argentina Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2012
|
|
|
|
